Robert A. Figlin, MD, on RCC: Results From the ADAPT Trial
2017 ESMO CongressRobert A. Figlin, MD, of Cedars-Sinai Medical Center, discusses an interim analysis of phase III findings on rocapuldencel-T, an individualized immunotherapy, for newly diagnosed patients with metastatic renal cell carcinoma (Abstract 1137O).
Related Videos
Marleen Kok, MD, PhD, on Triple-Negative Breast Cancer: Results From the TONIC Trial
Marleen Kok, MD, PhD, of The Netherlands Cancer Institute, discusses findings from an adaptive phase II noncomparative trial of nivolumab after induction treatment in triple-negati...
Domenica Lorusso, MD, PhD, on Cervical Cancer: Results From a Trial on Treatment Regimens
Domenica Lorusso, MD, PhD, of the National Cancer Institute of Milan, discusses neoadjuvant chemotherapy followed by surgery vs concurrent cisplatin and radiation therapy in patien...
Mansoor Mirza, MD: Ovarian Cancer Treatment and Quality of Life
Mansoor Mirza, MD, of Copenhagen University Hospital, discusses quality of life in patients with recurrent ovarian cancer treated with niraparib (Abstract 930O).
Jaafar Bennouna, MD, on Colorectal Cancer: Clinical Trial Findings on Targeted Treatments and Chemotherapy
Jaafar Bennouna, MD, of the University of Nantes, discusses findings from a phase II French study of bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab p...
Michèle Beau-Faller, MD, PhD, on NSCLC: Biomarker Findings From the French Cooperative Thoracic Intergroup
Michèle Beau-Faller, MD, PhD, of the Hôpital de Hautepierre & Institut Régional du Cancer, discusses study results on ultrasensitive detection of EGFR T790M mutation b...
